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Studies have shown that the alternative splicing of caspase 9 and the phosphostatus of SR proteins, a conserved family of splicing factors, are regulated by
chemotherapy and de novo ceramide via the action of protein phosphatase-1 (PP1). Two
RNA splice variants are derived from the caspase 9 gene, pro-apoptotic caspase 9a and
anti-apoptotic caspase 9b, via alternative splicing by either the inclusion or exclusion of an
exon 3, 4, 5 , and 6 cassette. In this study, the link between SR proteins and the alternative
splicing of caspase 9 was established. Sequence analysis of the exon 3, 4, 5 , and 6 cassette
of the caspase 9 gene identified five possible high affinity sequences for interaction with
vii

...
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the SR protein, SRp30a, a well-established regulator of exon inclusion/exclusion.
Replacement mutagenesis identified purine-rich sequences between exons 4 and 5 and
wthin exon 6 as important for binding SRp30a and required for expression of the caspase
9a splice variant. In vitro binding assays coupled with competitor studies demonstrated
specific binding of RNA trans-acting proteins and SRp30a with these sequences.
Furthermore, SDS-PAGE analysis of cross-linked RNA trans-acting factors with these
possible RNA cis-elements revealed the specific binding of an approximate 66, 56, 45, and
38 kDa proteinlprotein complex to these sequences. A previous application of RNAi
technology to downregulate SRp30a in A549 lung adenocarcinoma cells induced an
approximately 75% decrease in SRp30a expression and induced a dramatic change in the
ratio of caspase 9alcaspase 9b. Therefore, these studies have identified SRp30a as a major
regulator of the alternative splicing of caspase 9 directly linking de novo ceramide
generation, PP1, and SRp30a as the signal transduction pathway regulating the expression
of caspase 9.

CHAPTER 1 Introduction
Overview of Apoptosis and the roles of Caspase 9a and Caspase 9b

Apoptosis (used here interchangeably with programmed cell death) is a mechanism
(or group of mechanisms) by which cells execute endogenous programs of cell death, often
in response to adverse external or internal signals or sources of injury. In the case of
cancer, interference with this system of programmed cell death can lead to expansion of
deleterious cells. Apoptosis is regulated by multiple factors through complex mechanisms.
It has become well established that many inducers of apoptosis (e.g. chemotherapy)
activate caspases, and that the activation of these cysteine proteases is perhaps the point of
irreversible commitment to the onset of apoptosis. In normal, healthy cells, a protein
known as cytochrome c is sequestered between the inner and outer membranes of
mitochondria (1). In the presence of apoptotic death inducing stimuli, such as
chemotherapeutics or oxygen free radicals, monomers of a protein known as Bax migrate
from the cytosol to the outer membranes of the mitochondria, homodimerize, and form a
channel permitting ions to flow into the intermembranous space (1). This ion flux, through
an unknown mechanism, triggers cytochrome c to be released into the cytosol where it
binds to an adaptor protein known as Apaf- 1. Apaf- 1 then binds pro-caspase 9 and using
the energy from the hydrolysis of ATP, pro-caspase 9 autoproteolyzes into the active
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caspase 9 (2). The trimeric complex of pro-caspase 9 with cytochrome c and Apaf-1,
known as the apoptosome, is shown in Figure 1. Caspase 9 is a member of the caspase
family of proteases that functions as an initiator caspase. Active caspase 9 cleaves procaspase 3 into the active caspase 3 which cleaves additional substrates and leads to cell
death (2).

Caspase 9 has two antagonistic isoforms in programmed cell death: the proapoptotic caspase 9a and the pro-survival caspase 9b as shown in Figure 2. The caspase 9
gene is composed of eight introns and nine exons. Of these nine exons, the exon 3, 4, 5,
and 6 cassette encodes for the catalytic domain of caspase 9. If this cassette is included, the
caspase 9a splice variant is produced and if it is excluded, the caspase 9b splice variant is
produced. The caspase 9b variant lacks the catalytic protease domain and acts as a
dominant negative to the caspase 9a splice variant such that the translated caspase 9b
competes for Apaf-1 binding and also heterodimerizes with caspase 9a preventing it from
being activated. In this way, caspase 9b acts as an anti-apoptotic factor. This suggests that
alternative splicing, such as the alternative exon inclusion of caspase 9, may be an
important mechanism in the regulation of cell fate.
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Figure 1. Overview of the role of Caspase 9 in apoptosis.
The activation of caspase 9 occurs by pro-caspase 9 forming a trimeric complex known as
the apoptosome with two other proteins, apaf-1 and cytochrome c. This trimeric complex
utilizes the energy released from the hydrolysis of ATP to cleave pro-caspase 9 into an
activated caspase 9 and initiating the apoptotic cascade.
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Figure 2. Overview of Caspase 9 structure and its splice
variants. Two splice variants can be formed from caspase 9 pre-mRNA, caspase 9a and
caspase 9b. Determination of which splice variant is produced depends on whether the exon 3,4,5,
6 cassette is included or excluded. When the exon 3,4, 5, 6 cassette is included during the splicing
process, the pro-apoptotic caspase 9a rnRNA is expressed. When the exon 3, 4, 5, 6 cassette is
excluded during the splicing process, the anti-apoptotic caspase 9a rnRNA is expressed.

Role of Ceramide in Apoptosis

The bioactive sphingolipid, ceramide, is an important regulator of various stress
responses, apoptosis, and cellular senescence, and the formation of ceramide from the
hydrolysis of sphingomyelin or from de novo pathways has been observed in response to
agonists such as tumor necrosis factor-a, y-interferon, 25-dihydroxyvitamin D3,
interleukin- 1, ultraviolet light, heat, chemotherapeutic agents, fatty-acid synthase antigen,
and nerve growth factor. When these agonists have induced the formation of ceramide,
there are several targets of ceramide that are inducers of apoptosis as shown in figure 3.
These targets include ceramide activated protein kinase (CAPK), cathepsin D, and
serinelthreonine protein phosphatases PP1 (protein phosphatase 1) and PP2A (protein
phosphatase 2A) also known as ceramide activated protein phosphatases (CAPPs) (3).

Direct Targets of Ceramide
The prominent role of ceramide as a regulator of cellular mechanisms necessitated
the identification of these direct target enzymes previously mentioned. Cathepsin D has
been shown to play an important role in proteolysis as well as apoptosis. Heinrich et al.
found that cathepsin D is a direct target for ceramide and interaction with ceramide was
necessary to cleave pro-cathepsin D into active cathepsin D (3). Studies by Kagedal et al.
have shown that active cathepsin D, in response to oxidative stress, translocates from the
lysosome and that activation of caspase 3 is dependent on this activation and translocation

(4). It has been found that PKC-zeta (protein kinase C zeta) interacts directly with
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ceramide thereby modulating the response to TNF (15). The resulting activation of PKCzeta leads to the enhancement of splicing by increasing phosphorylation of hnRNPAl
leading to nuclear translocation and increased RNA binding affinity (16, 17). Kolesnick et
al. have reported on a ceramide-activated protein kinase (CAPK) in A-431 human
epidermal carcinoma cells and HL-60 human promyelocytic leukemia cells, but the
specificity of ceramide activation of CAPK, nor its role in intracellular signaling, have
been defined (5). Ceramide-activated protein phosphatase (CAPP), belongs to the family of
serinelthreonine protein phosphatases (6). CAPP was activated by ceramides that carried
different lengths of N-linked fatty acyl groups and was not activated by sphingomyelin,
sphingosine, or dihydroceramide (6). Also, CAPP activation in vitro closely matches the
specificity of various cellular activities of ceramide, including apoptosis (6). Ceramideinduced apoptosis is inhibited by okadaic acid, an inhibitor of serinelthreonine protein
phosphatases, which is additional evidence for a role of CAPP in mediating ceramide
responsiveness (6). There are two types of ceramide-activated protein phosphatases, which
inclde the serinelthreonine -specific protein phosphatases PPl and PP2A (7). Both PP2A
and PP1 have been reported to be targets for natural ceramides in vitro and in vivo (7).

Alternath
Splicing (e.g. Caspase 9)
Apoptosis

Figure 3. Overview of the role of ceramide in apoptosis.

several
putative and direct targets of ceramide action have been identified. Of these, those that couple ceramide
generation with downstream inducers of apoptosis include: ceramide activated protein kinase (CAPK),
cathepsin D, and serinelthreonine protein phosphatases PP1 (protein phosphatase l), PP2A (protein
phosphatase 2A), and PKC (protein kinase C) (3).

Ceramide Metabolism
Formation of ceramide from the agonist induced hydrolysis of sphingomyelin (8)
was shown in HL-60 human promyelotic leukemia cells treated with ercalcitriol. This and
other agonists that serve to induce the hydrolysis of sphingomyelin suggests that a
common theme of this group of agonists is associated with their different effects on growth
suppression (6). In different cell systems, the ceramide formed downstream from these
agonists induces either cell differentiation, cell-cycle arrest, apoptosis or cell senescence,
and this suggests a role for ceran~idein growth arrest and suppression (6).

The de novo pathway of ceramide synthesis has emerged as being responsive to
agonist stimulation (6) with ceramide generated by this pathway capable of exerting
biological actions (6). As shown in figure 4, condensation of serine and palmitoyl CoA by
serine palmitoyltransferase (SPT) initiates the pathway and generates ketosphinganine
which is then reduced, N-acylated, and desaturated by addition of the 4-5 trans double
bond in a series of enzymatic steps, leading to the generation of ceramide (6). Ceramide
can also be synthesized by ceramide synthase acting on sphingosine, and the reverse step,
the synthesis of sphingosine can be accomplished by ceramidases acting on ceramide. In
addition ceramide can be synthesized from sphingomyelin using sphingomyelinase and the
reverse can be accomplished using sphingomyelin synthase.
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Figure 4. Overview of Ceramide Metabolism (3)

The Role Of SR Proteins In Splicing

SR proteins are a family of argininelserine rich domain containing proteins with
both roles in constitutive RNA splicing and as regulators of alternative pre-mRNA
processing (9). Spliceosome assembly requires many non-snRNP protein factors including
members of the SR protein family (10). Each SR protein contains one or two N-terminal
RNP-type RNA binding domains (RBDs) and a C-terminal domain enriched in Arg-Ser
dipeptide repeats (RS domain) (lo), and SR proteins were shown to function in pre-mRNA
splicing as both general and alternative splicing factors (10). In splicing deficient HeLa
extracts, they were found to allow the splicing of several different pre-mRNAs (lo), and in
another case, SR proteins were shown to modulate alternative splicing by affecting the
usage of competing 5' or 3' splice sites in a concentration dependent manner (10). SR
proteins are also required for the activity of splicing enhancer elements, which are RNA
sequences, most frequently found in exons that are needed to activate certain weak splice
sites (10). Specifically, the SR proteins, SRp30a and SRp30b have been shown to interact
with U1 snRNP-specific 70K protein (U1 70k), and the RS domains of both proteins are
required for this interaction (10). SRp30a has also been shown to bind 5' splice sites (10).
These protein-protein and protein-RNA interactions have the potential to bring the two
splice sites together across either the intron or the exon (10) and as splicing activators, SR
proteins bind specific sequences in RNA enhancers and form complexes with other
proteins (6). SR proteins are phosphorylated extensively in vivo and phosphorylation takes
place mainly on serine residues within the RS domain (10). Addition of the serine
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threonine phosphatase, PP1, to nuclear extract inhibits spliceosome assembly and
phosphorylation of SR proteins is required in the progression of A con~plexto B complex
of the spliceosome (10). Furthermore, alternative 5' splice selection is also affected (18).

Dephosphorylation of SR Proteins and alternative splicing of caspase 9

In addition, the generation of endogenous ceramide and PP1 activation was also
shown to mediate the alternative splicing of an apoptotic factor, caspase 9, in a manner that
promotes apoptosis. Ceramide treatment resulted in a decrease in the processing and
expression of the pro-survival caspase 9b isoform of caspase 9 with a concomitant increase
in the pro-apoptotic caspase 9a isoform. This effect required the generation of endogenous
ceramide through the de novo pathway, and more importantly, inhibitors of protein
phosphatase-1 abolished the ability of ceramide to affect the alternative splicing of caspase
9. A hypothesis linking de novo ceramide synthesis to the alternative splicing of caspase 9
is shown in figure 5. Interestingly, it has been found that increased expression of caspase
9a due to de novo ceramide production occurred in PP1-dependent manner. Thus, both the
phospho-state of SR proteins and the alternative splicing of caspase 9 are regulated by the
generation of de novo ceramide and subsequent PP1 activation. These data suggest that
alternative splicing may be an important mechanism for the regulation of apoptosis by
ceramide.
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The involvement of PP1 and endogenous ceramide in the dephosphorylation of SR
proteins and the effects on caspase 9 alternative splicing suggested that at least one SR
protein isoform was involved in this pathway. Previous studies using siRNA to SRp30a, in
A549 lung adenocarcinoma cells showed that SRp30a is a major regulator in the
alternative splicing of caspase 9 as shown in figure 6. A549 lung adenocarcinoma cells
were treated with 200 nM siSRp30a and western blot analysis revealed an approximate
85% downregulation of SRp30a (figure 6). RT-PCR analysis revealed a dramatic decrease
in the caspase 9alcaspase 9b ratio. In these studies, we identified five possible purine-rich
RNA sequences within the caspase 9 gene that correspond to the binding sites of SRp30a,
and function as RNA cis-elements in the alternative splicing of caspase 9.

Chemotherapy

..Increase in de novo ceramide

nCaspase

9a

Figure 5.
Hypothesis of the signal transduction pathway
mediating the alternative splicing of caspase 9. Chemotherapeutics act on ~ 5 4 9
cells leading to de novo ceramide synthesis. This in turn leads to the activation of protein phosphatase 1 (PP l),
which dephosphorylates SR proteins. Dephosphorylated SRp30a, an SR protein family member, binds to
purine-rich cis-elements of the exon 3 , 4 , 5, 6 cassette of caspase 9 pre-mRNA in order to regulate inclusion and
exclusion of that cassette and favoring the caspase 9a splice variant.
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n

Figure 6. RNAi used to down regulate SRp30a.

RNAi technology was used
to downregulate SRp30a. A549 lung adenocarcinoma cells were treated with 200 nM siSRp30a, and
Western blot analysis revealed an approximate 85% downregulation of SRp30a (right panel). RT-PCR
analysis revealed a dramatic change in the caspase 9dcaspase 9b ratio (left panel). These studies were
performed bfiutumn Massiello of the Chalfant laboratory.

CHAPTER 2 Materials and Methods
Cell Culture: A549 lung adenocarcinoma cells were purchased from American
Type Tissue Culture Collection (http://www.atcc.org). These A549 cells were grown in
50% RPMI 1640 (Invitrogen) and 50% DMEM (Invitrogen) supplemented with Lglutamine, 10% (vlv) fetal bovine serum (Invitrogen), 100 U/ml of penicillin G sodium
(Invitrogen), and 100 pglml of streptomycin sulfate (Invitrogen). Cells were maintained at
less than 80% confluency under standard incubator conditions (humidified atmosphere,
95% air, 5% COz, 37" C).

Electromobility Shift Assay: The following sequences were used for FITC-tagged RNA
oligonucleotides: In Exon 3: r(5'Fl- gagaguuugaggggaaau), Between Exon 4 and Exon 5:
r(5'Fl- uggaggaccaugggagguaggac) and in Exon 6: r(5'Fl- ugggagggaagcccaagcu). The
following sequences were used for RNA oligonucleotide competitors without fluorescein:
In Exon 3: r(5'-ugaggggaaau), Between Exon 4 and Exon 5: r(5'- augggaggua) and in
Exon 6: r(5'- ugggagggaagc). RNA binding reactions were performed in a final volume of
25 p1 containing: 100 ng of fluorescein-oligonucleotide, 50 pg nuclear protein extract or 50
pg of recombinant SRp30a (generously provided by Dr.Adrian Krainer, Cold Harbor
Springs Laboratory, New York), 40 U RNASIN, and 11.3 pg tRNAs in buffer composed
of 50 mM HEPES, 5 mM DTT, 625 mM KC1, 5 mM DTT, 5 mM EDTA, and 0.125%

16
NP40. The reaction mixtures were incubated at 25' C for 30 minutes and then crosslinked
with ultraviolet light for 30 minutes. Half of these samples were loaded on a 5% TBE
CriterionTM Precast Gel (BioRad) for electrophoretic separation of RNA-protein(s)
complexes for 1.5 hours at 115 volts at 4' C. The gel was then scanned using Molecular
Imager@ FX (BioRad) with a 488nm EX (530 nm BP) laser. The Molecular Imager@ FX
(BioRad), performs densitometry analysis and reveals differences in a given scan only
within the linear range of statistical significance. An equal volume of 2

x

Laemmli buffer

(50 mM Tris-HC1, pH 6.8, 2% SDS, 10% glycerol, 0.04% bromophenol blue, and 250 mM
p-mercaptoethanol) was added to the other half of the samples which were boiled for 10
minutes. These samples were run on a 10% Tris-HCL CriterionTMPrecast Gel (BioRad) for
electrophoretic separation of RNA-protein(s) complexes for 1.5 hours at 50 volts through
the stacking gel and then at 100 volts at 25' C. For supershift reactions, antibody to
SRp30a (provided by Dr. Adrian Krainer, Cold Harbor Springs Laboratory, New York
(1 :10 diluted)) or non-specific IgG (1 mg/mL and 1: 10 diluted (Sigma)) was added 20 min
after addition of the oligonucleotide with an additional 30 min of binding time at 4' C.
Samples were then subjected to electrophoretic separation and analyzed as described
above.

Reverse Transcription Polymerase Chain Reaction (RT-PCR) Assay: Total RNA from

A549 cells was isolated using the RNeasy kit (Qiagen) per manufacturer's protocol. This
kit allows the investigator to lyse cells and remove all cellular components including
lipids, proteins, and DNA and purify only RNA. This is done in an RNase free
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environment. 1 pg of A549 total RNA was reverse transcribed using Superscript I1 reverse
transcriptase (Invitrogen) and oligo(dT) as the priming agent. After 50 min incubation at
42 "C, the reactions were stopped by 70" C heating for 15 min. Template RNA was then
removed using RNase H (Invitrogen).

For evaluating the expression of caspase 9 splice variants derived from the minigene, an
upstream vector 5' primer to caspase 9 (5' TCACTATAGGGAGACCCAAGC) and a 3'
primer E7A (5' AAGATGTCACTGGGTGTGGGCAAACTAGA) (Genosys, Inc.) were
used. Using these primers, 20% of the reverse transcriptase reaction was amplified for
35 cycles (94" C, 30s melt; 63" C, 30 s anneal; 72" C, 1 min extension) using Platinum Tag
DNA polymerase (Invitrogen). The RT-PCR reaction was examined by 1.5% agarose gel
electrophoresis and scanned on a Molecular Imager@ FX (BioRad). The Molecular
Imager@ FX (BioRad), performs densitometry analysis and reveals differences in a given
scan only within the linear range of statistical significance.

Nuclear Extracts: Nuclear extracts were prepared from A549 lung adenocarcinoma cells

according to the method of Dignam et al. (11) by Autumn Massiello.

Protein

concentrations were determined by a modification of the Bradford method using the BioRad protein assay reagent (Bio-Rad).
Protein Extraction: Cells were lysed with 0.1 mL of 2

x

Laemmli buffer (50 mM Tris-HC1,

pH 6.8, 2% SDS, 10% glycerol, 0.04% bromophenol blue, and 250 mM p-mercaptoethanol)
after resuspension in 0.1 mL of ice-cold phosphate-buffered saline (PBS). Samples were
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boiled for 10 min and either examined directly by 10% SDS-polyacrylamide gel
electrophoresis or stored at -20' C.
Western Immunoblotting: Total protein lysate (20 pg) was subjected to 10% SDS-PAGE.

Proteins were transferred to polyvinylidene difluoride membrane (Bio-Rad) and blocked in
5% milk, 1 x PBS-T (M-PBS-T) for 2 h. The membrane was incubated with anti-SRp30a
(provided by Dr. Adrian Krainer, Cold Harbor Springs Laboratory, New York (1:100
diluted)) or anti-a-tubulin (Santa Cruz Biotechnology (1:2000 diluted)) for 2 h in M-PBST followed by 3 washes with PBS-T. The membrane was then incubated with a secondary
antibody of horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (antiSRp3Oa) or horseradish peroxidase-conjugated anti-mouse IgM (Cal-Biochem) (anti-atubulin) for 45 min followed by 3 washes with PBS-T. Immunoblots were developed using
Pierce ECL reagents and Bio-Max film.

Replacement Mutagenesis: The caspase 9 minigene was cloned into the vector

pcDNA3.1(-) Zeocin purchased from Invitrogen. The five sequences selected for
replacement mutagenesis are shown in figure 7. To mutate these purine-rich sequences in
Exon 3, between Exons 4 & 5, between Exons 5 & 6, Exon 6, and Exon 6 & 7, the
Quikchange I1 XL Site-Directed Mutagenesis Kit by Stratagene was used. This kit enables
the investigator to introduce mutations into a cloned gene by several techniques. First, the
kit provides instructions on primer design with regards to % mismatch, length, and GC
content. Secondly, it provides the reagents for mutant strand synthesis, digestion of
parental strand, and the subsequent transformation of bacterial cells. To mutate the selected
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purine-rich sequences in the caspase 9 minigene and for efficient screening of mutants,
these purine-rich sequences were mutated to Hind I11 sites. The mutagenesis primers used
for

the

Exon

3

mutant

are

5'

CAGGTGCTCTTGAGAGTTTGAAGCTTGATGCAGATTTGGTGAG

3'

and

3'GTCCACGAGAACTCTCAAACTTCGAACTACGTCTAAACCACTC

5'.

The

mutagenesis

primers

used

for

the

4

Exon

and

5

mutant

are

3' and 3'

GCCCTTACATCTGGAGGACCATAAGCTTTAGGACGGCCCAGCGGC
CGGGAATGTAGACCTCCTGGTATTCGAAATCCTGCCGGGTCGCCG
mutagenesis

primers

used

for

Exon

5

6

and

5'

5'.

mutant

The

are

5'

CTGGGAGAAGCCCTCTGGGAGAAGCTTTGCAGAGACCAGGTCTGC 3' and 3'
GACCCTCTTCGGGAGACCCTCTTCGAAACGTCTCTGGTCCAGACG
mutagenesis

primers

used

for

the

6

Exon

5'.

mutant

are

CCAGCTGCCCCAGCCTGGGAAGCTTTCCCAAGCTCTTTTTCATCC 3'
GGTCGACGGGGTCGGACCCTTCGAAAGGGTTCGAGAAAAAGTAGG
mutagenesis

primers

used

for

the

Exon

6

and

GGGTGGGTCTGGTGGGGAAGCTTCCGCCACCTGCTTC

7

and
5'.

mutant
3'

The

and

are

5'
3'
The
5'
3'

CCCACCCAGACCACCCCTTCGAAGGCGGTGGACGAAG 5'. The resulting plasmids
were purified to be endotoxin free using the services of the Molecular Biology Core
Facility of the Massey Cancer Center of Virginia Commonwealth University.
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Sequence
1

2

.........
.........

Location
Exon 3 (18,333-1 8,339 bp)
Bnv Exons 4&5 (19,441 -19,446 bp)
Bnv Exons 5&6 (20472 - 20478 bp)

Exon 6 (21,582-21,588 bp)
Bnu Exon 6&7 (21648-21653 bp)

Figure 7. The five purine-rich sequences of capase 9 pre-mRNA
to undergo replacement mutagenesis.

Sequence VerlJication of Minigene Splice Variants: In order to ensure that the sequences of
the splice variants of the caspase 9 minigene correspond t o the actual sequences of the
caspase 9a and 9b splice variants minus Exon 1, Exons 8, and Exon 9, the cloned caspase 9
minigene (figure 8) was transfected into A549 lung adenocarcinoma cells. After 24 hours,
RNA was isolated from the cells using Qiagen's RNeasy Mini Kit (described previously).
RT-PCR was performed as outlined above. Once the PCR reactions were examined by
1.5% agarose gel electrophoresis, bands on the gel suspected of being the caspase 9a
variant and the caspase 9b variant were removed from the gel, and the RT-PCR products
were isolated using the Qiagen MinElute Gel Extraction Kit. This kit allows the
investigator to isolate DNA from an agarose gel by dissolving the agarose and eluting it on
a column followed by the elution of purified DNA. These RT-PCR products were sent to
SeqWright DNA Technology Services to be sequenced and their sequences were verified
by

checking

their

exon
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1. Step 1: High Fidelity PCR of the Genomic Gene Pieces of Caspase 9

2. High Fidelity PCR of Caspase 9 PCR fragments with Restriction Sites.
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Figure 8. Structure and cloning of the caspase 9 minigene.

1)

The caspase 9 minigene was constructed by amplifying selected gene pieces of the caspase 9
gene using genomic DNA. This resulted in a caspase 9 minigene that excluded exon 1, exon 8,
and exon 9. 2) Restriction sites were then engineered into the caspase 9 minigene so that when
the caspase 9 minigene was digested with the corresponding restriction enzymes and the vector
used for cloning (pcDNA3.1/(-) Zeocin) was digested with these same enzymes, the caspase 9
minigene could be cloned into this vector and subsequently used for transfections.

CHAPTER 3 Results
Caspase 9 Minigene producing splice ratio similar to that of endogenous
caspase 9

Previously, a minigene plasmid to examine the alternative splicing of caspase 9 in
cells was constructed (figure 8). To examine whether this construct behaved in a similar
manner as the endogenous gene, the plasmid was transiently transfected into A549 cells.
Using an RT-PCR based assay that examines only the minigene produced RNA, the ratio
of minigene caspase 9a19b was determined to be 3.0, comparable to the endogenous ratio
of 2.0. The resulting RT-PCR products were visualized using agarose gel electrophoresis
(figure 9).

100 BP ladder

v

RT-PCR for C9 minigene

Figure 9. Transfection of A549s with the caspase 9 minigene
(N=3). After transfection with the caspase 9 minigene, the wild type rninigene produced the
caspase 9a (910 BP) and caspase 9b (446 BP) splice variants in a ratio (approximately 3:l)
analogous to that of the endogenous wild type caspase 9 gene (approximately 2: 1). These caspase 9
rninigene products were cloned into a TOP0 vector and sequence verified.

Caspase 9a Minigene Sequence Verification
NNNNNNNNNNNNNNNNNNGTANNGTTTTGTAATAAAAAAACCTATAAATATTCCGGATTATTCATACCGTCCCACCATC
GGGCGTGCTAGCGGATCCGAGCTCGAGATCTGCAGCTGGTACCCGGGTCTAGAATTGCCCTTTCACTATAGGGAGA
CCCAAGCTGGCTAGCGTTTAAACGGGCCCTCTAGACTCGAGGGAGTCAGGCTCTTCCTTTGTTCATCTCCTGCTTAGA
GGACACAGGCCAGGACATGCTGGCTTCGTTTCTGCGAACTAACAGGCAAGCAGCAAAGTTGTCGAAGCCAACCCTAG
AAAACCTTACCCCAGTGGTGCTCAGACCAGAGATTCGCAAACCAGAGGTTCTCAGACCGGAAACACCCAGACCAGTG
GACATTGGTTCTGGAGGATTCGGTGATGTCGGTGCTCTTGAGAGTTTGAGGGGAAATGCAGATTTGGCTTACATCCT
GAGCATGGAGCCCTGTGGCCACTGCCTCATTATCAACAATGTGAACTTCTG,CCGTGAGTCCGGGCTCCGCACCCGCA
CTGGCTCCAACATCGACTGTGAGAAGTTGCGGCGTCGCTTCTCCTCGCTGCATTTCATGGTGGAGGTGAAGGGCGAC
CTGACTGCCAAGAAAATGGTGCTGGCTTTGCTGGAGCTGGCGCGGCAGGACCACGGTGCTCTGGACTGCTGCGTGG
TGGTCATTCTCTCTCACGGCTGTCAGGCCAGCCACCTGCAGTTCCCAGGGGCTGTCTACGGCACAGATGGATGCCCT
GTGTCGGTCGAGAAGATTGTGAACATCTTCNATGGGACCAGCTGCCCCAGCCTGGGANGGAAGCCCAAGCTCTTTTT
CATCCAGGCCTGTGGTGGGGAGCAGAAAGACCATGGGTTTGAGGTGGCCTCCNCTTCCCCTGAAGANNANTCCCCT
NGNAGTAACCCCNANCCANATGCCACCCCGTTCCAGGANNNTTTGAGGANCTTCGACCAGCTGGACGCCNTATCTAG
TTTGNCNCN

Caspase 9b Minigene Sequence Verification
ANNNNNNNNNNNNNNNNNNTTCGTNNNNGTTTTGTAATAAAAAAACCTATAAATATTCCGGATTATTCATACCGTCCCA
CCATCGGGCGTGCTAGCGGATCCGAGCTCGAGATCTGCAGCTGGTACCCGGGTCTAGAATTGCCCTTTCACTATAGG
GAGACCCAAGCTGGCTAGCGTTTAAACGGGCCCTCTAGACTCGAGGGAGTCAGGCTCTTCCTTTGTTCATCTCCTGC
TTAGAGGACACAGGCCAGGACATGCTGGCTTCGTTTCTGCGAACTAACAGGCAAGCAGCAAAGTTGTTGTCGAAGCCAAC
CCTAGAAAACCTTACCCCAGTGGTGCTCAGACCAGAGATTCGCAAACCAGAGGTTCTCAGACCGGAAACACCCAGAC
CAGTGGACATTGGTTCTGGAGGATTCGGTGATGTCGAGCAGAAAGACCATGGGTTTGAGGTGGCCTCCACTTCCCCT
GAAGACGAGTCCCCTGGCAGTAACCCCGAGCCAGATGCCACCCCGTTCCAGGAAGGTTTGAGGACCTTCGACCAGC
TGGACGCCATATCTAGTTTGCCCACACCCAGTGACATCTTAAGGGCAATTCGAAGCTTAGGCCTGGTAAGCCTATCCC
TAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCACCATCACCATTGACGTCTCTAGCTTGGAGTCGA
CAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACT
GCATTCTAGTTGTGGTTNGTCCAAACTCATCAATGTATCTTATCATCTCTCGACTCTGCTGAAGAGGAGGAAATTCTCC
TTGAAGTTTCCCTGGTGTTCAAAGTTTGCACCANACGCANCTCTGTTCACTGGTCCGGCGTATTAAAACA
CGATACATTGTTATTAGTACATTTATTAAGCGCTAGATTCTGTGCGTTGTNGANTTACAGAN

Figure 10. Sequence Verification of the caspase 9 splice variants
produced by the caspase 9 minigene. Shown above are the sequences of the
isolated RT-PCR products of caspase 9a and 9b. After obtaining the these sequences, they were
verified using the NCBI database as the exact sequences of the endogenous caspase 9a splice
variant and caspase 9b variant minus exons 1, 8, and 9 and containing the expected pcDNA3. I(-)
Zeocin sequence.

Sequence Verification of the caspase 9 splice variants produced by the caspase 9
minigene
The PCR products of the splice variants caspase 9a and caspase 9b shown in figure
9 were removed from the agarose gel, cloned into a pBlueBac4.5IV5-His-TOP0 vector
from Invitrogen, and sequenced using SeqWright DNA Technology Services. Figure 10
shows that the caspase 9 splice variants produced by the caspase 9 minigene are the exact
sequences of the endogenous caspase 9a splice variant and caspase 9b variant minus exons
1, 8, and 9 and containing the expected pcDNA3.1(-) Zeocin sequence.

Replacement Mutagenesis of Sequences 1 , 2 , and 4 alters the splice ratio of caspase 9a
and 9b
Replacement mutagenesis was performed on five purine-rich sequences (Sequences
1-5 shown in figure 7) in the caspase 9 minigene as outlined in the Materials and Methods
section. Of these five sequences, three of them, when mutated, affected the splice ratio of
caspase 9a and caspase 9b. Visualized in figure 11 are the RT-PCR products from A549
cells transfected with caspase 9 minigene with two different mutations introduced into
sequences 2 and 4. The mutation of these sequences corresponding to the purine-rich
sequence between Exons 4 and 5 and the purine-rich sequence in Exon 6, induced a
decrease in the splice ratio of caspase 9alcaspase 9b. Therefore, when both sequences 2
and 4 are mutated, a decrease in the splice ratio of caspase 9alcaspase 9b is observed.

Visualized in figure 12 are the RT-PCR products from A549 cells transfected with
caspase 9 minigene with sequence 1 mutated. Mutating this sequence increased the splice
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ratio of caspase 9dcaspase 9b. Since this mutation results in an increase of the caspase
9dcaspase9b ratio, this purine-rich sequence in Exon 3 acts as a repressor element.
Mutagenesis of sequences 3 and 5 had no effect on the ratio of caspase 9dcaspase 9b.

+ Caspase9a
i

s

+- Caspasc 9b

Figure 11. Purine-Rich RNA Cis-Elements #2 and #4 Affect the
Alternative Splicing of Caspase 9 Pre-mRNA (N=6). I = loo BP ladder,
2= Vector Control, 3= Wild Type Caspase 9 Minigene, 4= E6 Mutant 4 minigene, 5= E4 and E5
Mutant 2 minigene. These two mutants shift the direction of the splice ratio toward caspase 9b.

Figure 12. Purine-Rich RNA Cis-Element #1 Acts As A
Repressor Element for the Caspase 9a Splice Variant (N=6). I=
100 BP ladder, 2= Vector Control, 3= Wild Type C9 Minigene, 4= E3 Mutant 1 minigene. After
mutating this purine-rich sequence in exon 3 the splice ratio shifts in the direction of caspase 9a
indicating that it acts as a repressor element.

RNAIProtein Binding Studies Using Electromobility Shifts and SDS PAGE

After the replacement mutagenesis on the five purine-rich sequences
yielded three sequences that were possible sites for binding RNA splicing factors,
fluorescein-tagged oligonucleotides corresponding to these three sequences were used in
electromobility shift assays and SDS-PAGE assays. Since the purine-rich sequence in
Exon 3 was a possible repressor element in caspase 9 pre-mRNA, the corresponding
fluorescein tagged oligonucleotide and its competitive inhibitor were used in EMSA assays
to examine if this oligonucleotide bound proteins from nuclear extracts, which are rich in
transcription factors and splicing factors. The EMSA competitor study in figure 13 showed
that the fluorescein-tagged exon 3 sequence bound RNA trans-factors and is effectively
inhibited by the addition of an unlabeled oligonucleotide corresponding to the purine-rich
exon 3. Thus, this sequence is a possible candidate for the binding of a repressor protein.

Those assays were repeated and subjected to SDS-PAGE analysis for determination
of the specific protein (or protein complex) size bound to the RNA sequence as shown in
figure 14. The RNA oligonucleotides used for this assay correspond to the purine-rich
sequences in sequence 1 and sequence 4. These results demonstrate the specific binding of
-66, 56, 45, 38 kDa proteins to the oligonucleotide sequence in exon 3 and an -66 kDa
protein(s) bound to the exon 6 RNA oligonucleotide sequence.

Exon 3 RNA Oligo

Figure 13. EMSA Competitor Studies for Sequence l(Exon 3)
Using A549 Nuclear Extracts (N=3). Lane 1- EMSA as described previously,
including nonspecific competitor oligo- gaauucgcacguua. Lane 2- EMSA as described previously,
including specific competitor oligo for exon 3 - ugggagggaagcc. The competition away in lane 2
shows that the purine-rich sequence in exon 3 binds proteins in the A549 nuclear extract.

Figure 14. SDS-PAGE Analysis To Determine Sizes of Protein
Complexes bound to RNA sequences (N=3). NSC= Nonspecific
Competitor and SC= Specific Competitor. These results demonstrate the specific binding of -66,
56,45,38kDa proteins to the oligonucleotide sequence in exon 3 (possible repressor element).
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Because the mutation in sequence 2 (Intron 4-5) shifted the ratio of the splice variants
in the direction of caspase 9b, the EMSA competitor studies and SDS-PAGE was repeated
using a fluorescein-tagged oligonucleotide corresponding to that sequence. In figure 15,
the EMSA and SDS-PAGE competitor studies showed that fluorescein-tagged
oligonucleotides corresponding to the purine-rich sequences in sequence 4 and sequence 2
bind specifically to RNA trans-factors. This was confirmed by competition studies. Thus,
sequence 2 binds trans-factors of sizes 66, 56, and 38 Kd, and sequence 4 also binds transfactor complexes of 66, 56, and 38 kD in size.

We hypothesized that SRp30a might bind sequence 2 and sequence 4 given that the
literature shows SRp30a having a strong affinity for purine-rich sequences. Thus, it was
important to establish whether or not SRp30a interacts with these sequences. Recombinant
SRp30a was obtained from a collaborating lab, and these EMSAs were repeated using this
recombinant SRp30a. As seen in figure 16, when the EMSA was repeated using
recombinant SRp30a, sequences 2 and 4 bound to SRp30a, indicating that these sequences
have a strong affinity for SRp30a.

Figure 16. EMSA Competitor Studies For Sequence 2 and 4
(Intron 4-5 and Exon 6) Using Recombinant SRp30a (N=3). I=
Control (IgG), 2= Intron 4-5 Oligo, 3= Exon 6 Oligo. In the control lane, there is no shift evident.
In lanes 2 and 3, a clear shift can be seen when recombinant SRp30a is used which shows the
strong affinity of SRp30a for these two purine-rich sequences, (These experiments were conducted
in colaboration with Autumn Massiello of the Chalfant laboratory).
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Additional confirmation that SRp30a bound to these sequences was done by
repeating the EMSA using both A549 nuclear extracts and recombinant SRp30a and the
inclusion of an antibody specific to SRp30a. In figure 17, addition of an antibody specific
to SRp30a induced a "supershift" with a concommitant decrease of SRp30alsequence 4
complex. This confirmed that SRp30a bound to these two purine-rich sequences that
regulate the inclusion of the exon 3,4,5,6 cassette of the caspase 9 gene.

Loss
of sldft

Figure 17. EMSA Supershift for Sequence 4 (Exon 6 oligo)
(N=3). The first two lanes are EMSAs using recombinant SRp30a and the last two lanes are
EMSAs using A549 nuclear extracts. Non-specific IgG antibody is used as a control for these
EMSAs, and IgG antibody specific to SRp30a is used to create both loss of shift and a supershift
indicating that SRp30a does bind to this purine-rich sequence (These experiments were conducted
in
collaboration
with
Autumn
Massiello
of
the
Chalfant
laboratory

Chapter 4 Discussion
Previously, our laboratory showed that siRNA to SRp30a changed the splice ratio
of caspase 9al9b showing a decrease in caspase 9a expression with a concon~itantincrease
in caspsase 9b expression. In this study, we showed that mutation of the purine-rich
sequences 2 and 4 (Intron 4-5 and Exon 6 of the caspase 9 gene) induced a decrease in the
splicing ratio of caspase 9alcaspase 9b. This finding demonstrated that these RNA ciselements are required for the inclusion of the exon 3, 4, 5, 6 cassette and are exonic
splicing enhancers. Furthermore, mutation of the purine-rich sequence in exon 3 induced
an increase in the caspase 9alcaspase 9b ratio acting as a repressor RNA cis-element. Both
exonic enhancers specifically bound RNA splicing factors, specifically SRp30a. These
findings are important for several reasons. First, the alternative splicing mechanism of
caspase 9 splicing is better defined. Second, these findings demonstrate a link between SR
proteins and the alternative splicing of caspase 9. Finally, these findings have direct
relevance to mechanisms governing the sensitization of cancer cells to chemotherapy.

Liu et a1 previously reported that SRp30a had an affinity for the purine-rich
sequences, RGAACAAC and AGGACRRAGC, based on SELEX binding studies where R
represents a purine (12). In additional studies they performed, they found exon splicing
enhancers (ESEs) with sequences, AGGAGGA, GACCCGG, CGCAGGG, CAGAGGU,
and GAGACGA bound SRp30a with high affinity and greatly enhanced splicing (12).
Furthermore, unpublished studies from our laboratory showed that siRNA against SRp30a
decreased the splice ratio of caspase 9alcaspase 9b. Based on these findings, we proceeded
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with replacement mutagenesis of five sites identified in caspase 9 pre-mRNA that are as
uncharacteristically purine-rich as the aforementioned sequences. Indeed, mutating
sequences 2 and 4 had a dramatic effect on the alternative splicing of caspase 9, reducing
the ratio of caspase 9alcaspase 9b. Binding studies using oligonucleotides that correspond
to these sequences demonstrated specific interaction of these sequences with RNA transfactors. Our laboratory further showed that these sequences interacted specifically with
SRp30a. This finding was important because it provided strong mechanistic evidence that
SRp30a plays an important role in alternative splicing of caspase 9. Thus, for the first time,
SRp30a was shown to be involved in regulating the inclusion of a large exon cassette as is
the case for caspase 9 pre-mRNA.

Given these findings, there are finally implications for a link between de novo
ceramide synthesis and the dephosphorylation of SR proteins favoring to the caspase 9a
phenotype. Although there is no current evidence directly linking dephosphorylation of SR
proteins to the alternative splicing of caspase 9, the SR protein SRp30a, is now directly
linked as an important regulator of this mechanism. As mentioned before, PP1 has been
reported as a target for activation by natural ceramides in vitro (9), and SR proteins have
been shown to be substrates of PP1 (9). Chalfant et a1 have reported that de novo ceramide
synthesis increases the ratio of caspase 9alcaspase 9b and in their experiments, inhibitors
to PP1 abolished this effect of ceramide on the splice ratio, thus showing that ceramide
altered the splice ratio in a PPl dependent manner (13). Because our laboratory showed
that siRNA against SRp30a decreased the splice ratio of caspase 9alcaspase 9b and SR
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proteins are known substrates of PP 1, the accumulated indirect evidence strongly suggests
a link between de novo ceramide synthesis and the dephosphorylation of SRp30a leading
to an increase in the splice ratio of caspase 9alcaspase 9b.

e
for therapy in lung adenocarcinoma cells. If
This leads us to a possible h h ~ r target
excessive phophorylation of SRp30a in the spliceosome leads to an anti-apoptotic(procancer phenotype) then a possible target could be the kinase that phosphorylates SRp30a.
Prasad et. a1 have reported that ClWSty (Clkl) is a protein kinase that when
autophosphorylated, phosphorylates

SR proteins (14). Which

SR proteins get

phosphorylated by ClWSty depends on the nature of the autophosphorylation that it
undergoes. From their experiments, they have found that when ClWSty autophosphorylates
on Tyr residues, but not SerIThr residues, the result is phosphorylation of SRp30a (14).
Interestingly, they found that SC35 is phosphorylated when SerIThr residues are
autophosphorylated by ClWSty, and that SRp40 is phosphorylated by ClWSty when no
autophosphorylation takes place (14).

It is evident that ClWSty is responsible for

phosphorylating several different SR proteins depending on its autophosphorylation status,
so this allows for different scenarios of targeted therapy. One possibility would be to treat
cells with antibodies specific to ClWSty, which are tagged with catalytic residues that alter
the tyrosine phosphorylation of ClWSty. This would be be a precise targeting of ClWSty
that would allow it to hnction as a kinase for all its other substrates except for SRp30a.
Perhaps this targeted therapy scheme seems too unrealistic, so a more reasonable approach
to therapy would be to introduce to adenocarcinoma cells siRNA to ClWSty to
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downregulate it, so that SRp30a would be less phosphorylated, and the catalytic activity of
PP1 on SRp30a would be more effective in yielding the pro-apoptotic caspase 9a
phenotype. Even this kind of treatment must be monitored very closely, because as
mentioned before, ClklSty phophorylates other SR proteins as well including SRp40 and
SC35. It is quite possible that excessive dephosphorylation of these SR proteins could have
undesirable consequences. Lastly, since we have found that sequence 1 (in Exon 3) acts as
repressor element,

which

when mutated,

favors

the pro-apoptotic

phenotype,

adenocarcinoma cells could be treated locally by transfecting them with a cloned full
caspase 9 gene with a silent mutation introduced in this purine-rich repressor sequence.
The silent mutation would allow for the coding of the same amino acids, but would not be
purine-rich. In this way, we could shift the splice ratio in the direction of caspase 9a while
still having a completely functional caspase 9a.

So, preliminary studies have shown that siRNA to SRp30a decreased the splice
ratio of caspase 9a19b. Furthermore, when the purine-rich binding sites for SRp30a in
Intron 4-5 and Exon 6 of the caspase 9 gene are mutated, there is also a decrease in the
splice ratio of caspase 9alcaspase 9b. Because of these findings we realize now that SR
proteins, specifically SRp30a, are part of the mechanism of the alternative splicing of
caspase 9 and that SRp30a fits into the cascade of de novo ceramide synthesis leading to
the alternative splicing of caspase 9. Finally, these findings allow for the possibility of new
types of chemotherapy to treat cancer.

42
Therefore in this study, we have identified two purine-rich sequences that act as
exonic splicing enhancers for the inclusion of the exon 3, 4, 5, 6 cassette of caspase 9 premRNA. The Chalfant laboratory demonstrated that these ESE's interact specifically with
SRp30a. Therefore, the finding that SRp30a is part of the mechanism of the alternative
splicing of caspase 9 pre-mRNA finally provides the critical link to PP1 and de novo
ceramide synthesis. Lastly, these findings allow for the possibility of new types of
chemotherapy to treat cancer as well as possible diagnostic applications.
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